Interferon beta-1a placebo

DRUG2 trials

Conditions

Relapsing Multiple SclerosisRelapsing-Remitting Multiple Sclerosis

Phase 3

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

CompletedNCT01064401

BiogenRelapsing-Remitting Multiple Sclerosis

Start: 2010-05-31End: 2014-07-31Updated: 2016-07-11

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

CompletedNCT02047734

CelgeneRelapsing Multiple Sclerosis

Start: 2013-12-03End: 2017-04-13Updated: 2021-02-11

European Journal of Neurology2025-06-011 citations

Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis.

2025-04-012 citations

Monitoramento do Horizonte Tecnológico: Ozanimode para o tratamento da esclerose múltipla

Jornal de Assistência Farmacêutica e Farmacoeconomia2024-11-30

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

Journal of Comparative Effectiveness Research2024-08-192 citations

Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis (P10-6.013)

Neurology2024-04-09

Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial

Multiple Sclerosis Journal2023-12-214 citations

Relationship Between Infections and Absolute Lymphocyte Count During Phase 3 and Open-label Extension Trials of Ozanimod in Patients With Relapsing Multiple Sclerosis (P7-3.002)

Neurology2023-04-25

Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010)

Neurology2023-04-25

Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.

2023-04-1820 citations

2221 Evaluating no evidence of disease activity (NEDA) with Ozanimod in patients with relapsing multiple sclerosis (RMS): post hoc analysis of phase 3 RADIANCE and DAYBREAK

Abstracts2022-08-01

P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

The American Journal of Gastroenterology2021-12-017 citations

067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials

2021-08-012 citations

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Therapeutic Advances in Neurological Disorders2021-01-016 citations

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

2019-09-03192 citations

Gray Matter Volume Loss Is Increased in Younger Patients With Relapsing Multiple Sclerosis but Minimized by Ozanimod: Experience From the Ozanimod Phase 3 Program (P5.2-056)

Neurology2019-04-09

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

Multiple Sclerosis Journal2018-07-2549 citations

Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.006)

Neurology2018-04-105 citations

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

Multiple Sclerosis Journal2017-05-0944 citations

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

Multiple Sclerosis and Related Disorders2016-11-1312 citations

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.

2016-07-1314 citations

6 more papers not shown

Interferon beta-1a placebo

Sponsors

Conditions

Phase 3

Related Papers